Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2283–2291 | Cite as

Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria

  • Yuzhou Huang
  • Xinjian Liu
  • Fangfei Chen
  • Wenzhe Zhou
  • Hongmin Li
  • Zhangbiao Long
  • Chen Yang
  • Miao Chen
  • Bing HanEmail author
Original Article

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic disease with thrombosis as a major complication. The mechanism of thrombosis and related risk factors in PNH patients are still not well characterized. We retrospectively enrolled 99 patients with newly diagnosed PNH at our institute from 2011 to 2016. According to binary logistic regression model analysis, we first identified four baseline clinical risk factors which may be associated with incidence of thrombosis in the PNH cohort, including PNH clone sizes (fluorescent aerolysin of neutrophil) ≤ 80 (OR 1.056, 95%CI 1.016–1.097, P = 0.005), hemoglobin ≤ 75 g/L (OR 4.202, 95%CI 0.984–17.954, P = 0.053), platelet > 100 × 109/L (OR 6.547, 95%CI 1.490–28.767, P = 0.013) and rs495828 = G (OR 5.243, 95%CI 1.314–20.916, P = 0.019). These independent risk factors were combined together to develop a risk model to evaluate thrombosis risk (AUC = 0.756, 95%CI 0.607–0.905, P < 0.001). Our risk model revealed a higher cumulative incidence of thrombosis and an earlier thrombosis events in PNH patients with high risk (risk score ≥ 23) compared with those with low risk (risk score < 23, P < 0.001 and P = 0.043, respectively). Although with some limitations, we set up a prediction model for thrombosis risk in patients with PNH for the first time, but it needed to be verified in a prospective study with larger patients and longer follow-up time in the future.

Keywords

Paroxysmal nocturnal hemoglobinuria (PNH) Thrombosis Risk score Prediction model 

Notes

Authors’ contribution

Y.H. and B.H. designed the study and wrote the manuscript. Y.H. analyzed clinical and experimental data. X.L. helped analyzed the risk model. C.Y. and M.C. helped to design the study. Z.L. and W.Z. collected the samples, performed genotyping, and helped to analyze the data. H.L. and F.C. helped to perform genotyping. All authors reviewed the manuscript finally. Y.H., M.C., and B.H. approved the final submission of the manuscript.

Funding information

This study was supported by grants from the Chinese Academy of Medical Sciences (CAMS) innovation fund for medical sciences (2016-I2M-3-004), The National Key Research and Development Program of China (2016YFC0901500), and Beijing Natural Science Foundation (7192168).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the PUMCH Ethics Committee.

Informed consent

Informed consent was obtained before study start from all individuals included in the study.

Supplementary material

277_2019_3770_MOESM1_ESM.pdf (190 kb)
ESM 1 (PDF 190 kb)
277_2019_3770_MOESM2_ESM.pdf (201 kb)
ESM 2 (PDF 201 kb)
277_2019_3770_MOESM3_ESM.pdf (158 kb)
ESM 3 (PDF 158 kb)
277_2019_3770_MOESM4_ESM.pdf (161 kb)
ESM 4 (PDF 160 kb)

References

  1. 1.
    Hill A, DeZern AE, Kinoshita T, Brodsky RA (2017) Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 3:17028.  https://doi.org/10.1038/nrdp.2017.28 CrossRefGoogle Scholar
  2. 2.
    Mohammed AA, El-Tanni H, Atiah TA, Atiah AA, Atiah MA, Rasmy AA (2016) Paroxysmal nocturnal hemoglobinuria: from bench to bed. Indian J Hematol Blood Transfus 32(4):383–391.  https://doi.org/10.1007/s12288-016-0654-2 CrossRefGoogle Scholar
  3. 3.
    Boyce S, Eren E, Lwaleed BA, Kazmi RS (2015) The activation of complement and its role in the pathogenesis of thromboembolism. Semin Thromb Hemost 41(6):665–672.  https://doi.org/10.1055/s-0035-1556732 CrossRefGoogle Scholar
  4. 4.
    Schrezenmeier H, Muus P, Socie G, Szer J, Urbano-Ispizua A, Maciejewski JP, Brodsky RA, Bessler M, Kanakura Y, Rosse W, Khursigara G, Bedrosian C, Hillmen P (2014) Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica 99(5):922–929.  https://doi.org/10.3324/haematol.2013.093161 CrossRefGoogle Scholar
  5. 5.
    Day ISCWT (2014) Thrombosis: a major contributor to global disease burden. Thromb Res 134(5):931–938.  https://doi.org/10.1016/j.thromres.2014.08.014 CrossRefGoogle Scholar
  6. 6.
    Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 121(25):4985–4996.  https://doi.org/10.1182/blood-2012-09-311381 CrossRefGoogle Scholar
  7. 7.
    DeZern AE, Brodsky RA (2015) Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia. Hematol Oncol Clin North Am 29(3):479–494.  https://doi.org/10.1016/j.hoc.2015.01.005 CrossRefGoogle Scholar
  8. 8.
    Griffin M, Munir T (2017) Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide. Ther Adv Hematol 8(3):119–126.  https://doi.org/10.1177/2040620716681748 CrossRefGoogle Scholar
  9. 9.
    Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M (2007) Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 5(3):642–645.  https://doi.org/10.1111/j.1538-7836.2007.02379.x CrossRefGoogle Scholar
  10. 10.
    Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110(12):4123–4128.  https://doi.org/10.1182/blood-2007-06-095646 CrossRefGoogle Scholar
  11. 11.
    de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, De GS, Maury S, Cahn JY (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112(8):3099–3106CrossRefGoogle Scholar
  12. 12.
    Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124(18):2804–2811.  https://doi.org/10.1182/blood-2014-02-522128 CrossRefGoogle Scholar
  13. 13.
    Hoekstra J, Leebeek FW, Plessier A, Raffa S, Darwish Murad S, Heller J, Hadengue A, Chagneau C, Elias E, Primignani M, Garcia-Pagan JC, Valla DC, Janssen HL (2009) European network for vascular disorders of the L (2009) paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51(4):696–706.  https://doi.org/10.1016/j.jhep.2009.06.019 CrossRefGoogle Scholar
  14. 14.
    Long Z, Du Y, Li H, Han B (2017) Polymorphism of the ABO gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. Oncotarget 8(54):92411–92419.  https://doi.org/10.18632/oncotarget.21361 CrossRefGoogle Scholar
  15. 15.
    Dezern AE, Borowitz MJ (2018) ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. Cytometry B Clin Cytom 94(1):16–22.  https://doi.org/10.1002/cyto.b.21608 CrossRefGoogle Scholar
  16. 16.
    Borowitz MJ, Craig FE, Digiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ, Clinical Cytometry S (2010) Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 78(4):211–230.  https://doi.org/10.1002/cyto.b.20525 Google Scholar
  17. 17.
    Sullivan LM, Massaro JM, Sr D'Agostino RB (2004) Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med 23(10):1631–1660.  https://doi.org/10.1002/sim.1742 CrossRefGoogle Scholar
  18. 18.
    Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK (2013) Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean registry. Int J Hematol 97(6):749–757.  https://doi.org/10.1007/s12185-013-1346-4 CrossRefGoogle Scholar
  19. 19.
    Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, Decastro CM, Hall S, Kanamaru A, Sullivan KM, Mizoguchi H, Omine M, Kinoshita T, Rosse WF (2004) Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine 83(3):193–207CrossRefGoogle Scholar
  20. 20.
    Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, Duval A, Schved JF, Fischer AM, Socie G, French Society of H (2010) Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 95(4):574–581.  https://doi.org/10.3324/haematol.2009.016121 CrossRefGoogle Scholar
  21. 21.
    Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y, Tsuda H, Kang D, Hamasaki N (2005) Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 38(10):908–915.  https://doi.org/10.1016/j.clinbiochem.2005.05.006 CrossRefGoogle Scholar
  22. 22.
    Yu F, Du Y, Han B (2016) A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol 103(6):649–654.  https://doi.org/10.1007/s12185-016-1995-1 CrossRefGoogle Scholar
  23. 23.
    Zou N, Han B, Cai H, Xu Y, Wang X, Li RS, Shen T (2012) Clinical features of 76 Chinese patients with paroxysmal nocturnal haemoglobinuria. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 33(6):471–474Google Scholar
  24. 24.
    Ge M, Li X, Shi J, Shao Y, Zheng Y (2012) Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Ann Hematol 91(7):1121–1128.  https://doi.org/10.1007/s00277-012-1413-6 CrossRefGoogle Scholar
  25. 25.
    Green M, Styles T, Russell T, Sada C, Jallow E, Stewart J, Lazariashvili O, Lubomirova I, Cotlarciuc I, Sharma S, Han TS, Sharma P (2018) Non-genetic and genetic risk factors for adult cerebral venous thrombosis. Thromb Res 169:15–22.  https://doi.org/10.1016/j.thromres.2018.07.005 CrossRefGoogle Scholar
  26. 26.
    Taran LD (2003) Protein C system and thrombosis diseases. Ukr Biokhim Zh (1999) 75(1):18–24Google Scholar
  27. 27.
    Peacock-Young B, Macrae FL, Newton DJ, Hill A, Ariens RAS (2018) The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. Haematologica 103(1):9–17.  https://doi.org/10.3324/haematol.2017.177618 CrossRefGoogle Scholar
  28. 28.
    Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23(4):177–189.  https://doi.org/10.1016/j.blre.2009.04.001 CrossRefGoogle Scholar
  29. 29.
    Wiedmer T, Esmon CT, Sims PJ (1986) Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 68(4):875–880Google Scholar
  30. 30.
    Du Y, Long Z, Xie H, Zhuang J, Han B (2016) The preliminary research in paroxysmal nocturnal hemoglobinuria with thrombosis. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 37(4):318–323.  https://doi.org/10.3760/cma.j.issn.0253-2727.2016.04.014 Google Scholar
  31. 31.
    Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S (1997) A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16(9):965–980CrossRefGoogle Scholar
  32. 32.
    Van Bijnen ST, Van Heerde WL, Muus P (2012) Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost 10(1):1–10.  https://doi.org/10.1111/j.1538-7836.2011.04562.x CrossRefGoogle Scholar
  33. 33.
    Morange PE, Suchon P, Tregouet DA (2015) Genetics of venous thrombosis: update in 2015. Thromb Haemost 114(5):910–919.  https://doi.org/10.1160/TH15-05-0410 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yuzhou Huang
    • 1
  • Xinjian Liu
    • 2
  • Fangfei Chen
    • 1
  • Wenzhe Zhou
    • 1
  • Hongmin Li
    • 1
  • Zhangbiao Long
    • 1
  • Chen Yang
    • 1
  • Miao Chen
    • 1
  • Bing Han
    • 1
    Email author
  1. 1.Department of HematologyPeking Union HospitalBeijingChina
  2. 2.Department of Hematology, Henan Cancer Hospital, Institute of Hematology of Henan ProvinceAffiliated Cancer Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations